The U.K.'s National Institute for Health and Care Excellence cleared the use of Merck & Co. Inc.'s cancer drug Keytruda in previously untreated lung cancer patients under funding arrangements within the Cancer Drugs Fund, Reuters reported.

The agency did not recommend the routine use of the drug for newly diagnosed patients due to its high cost and uncertainties about overall survival benefits.